1.Prevention of multiple organ failure in early stage of severe burns with immediate fast fluid infusion in dogs
Faming CHEN ; Zongcheng YANG ; Shaoyu KANG
Journal of Third Military Medical University 1984;0(01):-
Fifty percent TBSA third degree burns was inflicted to 24 dogs and they were treated with immediate fluid infusion (8 dogs),delayed conventional infusion (n=8),and delayed fast infusion (n=8),It was found that in the immediate and delayed fast infusiong groups,strike volume,strike index, left ventricular strike work index,right ventricular strike index and femoral arterial pressure were maintained at a level more than 50% of the normal and were gradually restored.Their pulmonary artery wedge pressure was larger than 1.3 kPa.ALT and LDH were increased but never exceeded the preburn level.DB,TB,UN,Cr,PaO2,P(A-a)O2 were maintained in the normal range.MDA RCR,ADP/O,ATP,positive blood culture rate,mortality rate and morbility of multiple organ failure were all lower than those of the delayed conventional infusion group.It is believed that in the early stage of burn injury,the development of multiple organ failure can prevented effectively with immediate infusion and partially with delayed fast infusion while delayed conventional infusion exerts no protection at all.
2.Study on the Pharmacodynamic Substances of Simiao Wan for Treatment of Hyperuricemia and Gout Based on Disease and Syndrome Model
Yongchang ZENG ; Shaoyu LIANG ; Junhong WU ; Dandan XU ; Changqing LIU ; Kang HE ; Yu JIN ; Zhengzhi WU
Traditional Chinese Drug Research & Clinical Pharmacology 2024;35(8):1152-1162
Objective To explore the pharmacodynamic substances of Simiao Wan for the treatment of hyperuricemia and gout.Methods The pharmacological model of hyperuricemia was established.The chemical components in vivo and in vitro of Simiao Wan were analyzed by UPLC-Q-Exactive-MS.Based on the components absorbed in blood,the"active ingredient-target-pathway"network of Simiao Wan for regulating hyperuricemia and gout was constructed by network pharmacology method.The key ingredients were used for molecular docking with key targets[uricogenase(XDH),uric acid transporter(ABCG2,GLUT9,OAT1,URAT1)and inflammatory targets(PTGS2,TLR2,TLR4)]of hyperuricemia and gout.Finally,experimental verification was conducted according to the results of molecular docking.Our aim is to identify the key pharmacodynamic substances of Simiao Wan for the treatment of hyperuricemia and gout.Results Eighty-nine components of Simiao Wan were identified by UPLC-Q-Exactive-MS analysis,including 74 components absorbed in blood,which were confirmed as candidate ingredients.Network pharmacology was used to constructed"components absorbed in blood-target-pathway"network,and components absorbed in blood were matched with 116 targets of hyperuricemia and 173 targets of gout.It is involved in the regulation of biological processes,such as glucose and lipid metabolism,oxidative stress,inflammatory response,ERK1 and ERK2 cascade,MAPK cascade,PI3K signal transduction.Moreover,Simiao Wan plays a role in regulating the network of hyperuricemia and gout through regulating blood lipids and atherosclerosis,apoptosis,AGE-RAGE,TNF,PI3K-Akt,MAPK,TLRs,JAK-STAT,NF-κB and other signaling pathways.Molecular docking studies showed that berberine,phellodendrine,magnoflorine,jatrorrhizine,palmatine,obacunone,limonin,atractylodin,taxifolin,atractylenolide Ⅲ and β-ecdysterone had good affinity with uric acid synthase,uric acid transporter and inflammatory targets.Western Blot test showed that taxifolin negatively regulates the expression of URAT1.The above-mentioned compounds were the main pharmacodynamic substances of Simiao Wan for the treatment of hyperuricemia and gout.Conclusion This article describes the main pharmacodynamic substances of Simiao Wan in the regulation of hyperuricemia and gout,which can provides a scientific basis for the clinical application,improvement in quality evaluation and standard of Simiao Wan.
3.Mechanism prediction and validation of Kaixinsan in ameliorating neuroinflammation in Alzheimer’s disease
Dandan XU ; Yongchang ZENG ; Shaoyu LIANG ; Qi LIU ; Junhong WU ; Kang HE
China Pharmacy 2025;36(12):1476-1482
OBJECTIVE To predict and validate the potential mechanisms of Kaixinsan (KXS) in ameliorating neuroinflammation in Alzheimer’s disease (AD). METHODS Network pharmacology was employed to identify core anti- inflammatory components and key inflammatory targets of KXS for AD. Gene ontology (GO) functional annotation, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, and molecular docking were performed. Based on these findings, male SD rats were used to establish an AD model via chronic D-galactose induction. The effects of KXS on AD rats were evaluated, including quantitative behavioral score, learning and memory parameters (escape latency, platform crossings, platform quadrant distance and time), organ indexes (heart, liver, spleen, thymus), histopathological alterations in the hippocampus, and expressions of inflammation-related pathway proteins and their upstream/downstream regulators. RESULTS Core anti-inflammatory components of KXS for AD included gomisin B, panaxytriol, gomisin A, enhydrin, vulgarin and panaxydol, while key inflammatory targets involved nuclear factor-kappa B subunit 1( NFKB1), nuclear factor-κB p65( NF-κB p65), interleukin-1β( IL- 1β), IL-6, Toll-like receptor 4 (TLR4), tumor necrosis factor, nucleotide-binding domain leucine-rich repeat and pyrin domain- containing receptor 3 (NLRP3) and caspase-1 (CASP1). GO and KEGG pathway enrichment involved inflammatory response, phosphorylation and the NF-κB signaling pathway. Molecular docking confirmed strong binding affinities between core components and key targets. Animal experiments demonstrated that, compared to the model group, KXS significantly alleviated histopathological damage (e.g., neuronal shrinkage, reduced Nissl bodies in hippocampal CA1, CA3, and DG regions), increased organ indexes (except for liver index) and Nissl-stained positive cells, improved learning and memory performance, and reduced behavioral scores (at the 8 and 12 weeks of the experiment) and protein expression of NF- κB p65, phosphorylated NF- κB p65, TLR4, NLRP3, CASP1 and IL-1β. CONCLUSIONS KXS effectively mitigates neuroinflammation, reduces hippocampal neuronal injury, and enhances learning and memory ability in AD rats, potentially through suppressing the NF-κB signaling pathway and its upstream/ downstream regulators.